Is Enlicitide legal in the US?
Yes, FDA approved for lowering LDL cholesterol in adults with high cholesterol.
On July 15, 2026 the FDA approved enlicitide as Lipfendra (Merck), the first oral PCSK9 inhibitor, as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Approval was based on LDL lowering; the cardiovascular outcomes trial is still running.
Yes. Lipfendra was approved on July 15, 2026 for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It is an add-on to diet and exercise. 235
More on Enlicitide
Citations
- Ballantyne 2026, NEJM: oral PCSK9 inhibitor enlicitide in adults with hypercholesterolemia (CORALreef Lipids) doi.org
- Merck 2026: Lipfendra (enlicitide) prescribing information merck.com
- Merck 2026: Lipfendra approved by the FDA as the first oral PCSK9 inhibitor merck.com
- Journal of the American College of Cardiology 2026: enlicitide phase 3 report (DOI record) doi.org
- FDA: Novel Drug Approvals for 2026 fda.gov
Reference information only, not medical advice. Drawn from the Enlicitide article, fact-checked against the cited sources. No dosing anywhere on this site.